semaglutide medicine FDA approves obesity drug that helped people cut weight 15% Oral GLP-1 Medication Helps Patients

Earliest commercial launch Q1Q2 2028

RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation

While this can lead to meaningful weight loss and better blood glucose control, it can also trigger changes that make you feel dizzy or off balanceespecially early in treatment

Cani PD, Neyrinck AM, Maton N, Delzenne NM

Known Risks, Side Effects, and Safety Considerations The most common side effects are gastrointestinal including nausea, vomiting, and diarrhoea with additional class-related risks of pancreatitis and gallbladder disease

When it comes to reduction of weight-related issues like diabetes, heart disease risks and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), bariatric surgery far outpaces GLP-1s in reduction, and often removal, of these risks